申请人:British Technology Group Limited
公开号:US05652255A1
公开(公告)日:1997-07-29
A human or animal subject having a solid tumour is treated by administering to the subject therapeutically effective amounts of a nitric oxide (NO) synthase inhibitor and a compound which is an imidazole or 1,2,4-triazole derivative of formula (A) ##STR1## wherein X is selected from the group consisting of ##STR2## wherein R is hydrogen or a C.sub.1 -C.sub.6 alkyl group; each of R'.sub.1 to R'.sub.5 is independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 alkyl, hydroxy(C.sub.1 -C.sub.6 alkyl), phenyl, (C.sub.1 -C.sub.6 alkyl)phenyl and phenyl(C.sub.1 -C.sub.6 alkyl); m is 0 or 1; n is 1 or 2; and Z' represents a leaving group which has the potential for expulsion via an intramolecular cyclisation reaction and which is not negatively-charged; or a physiologically acceptable acid addition salt thereof.
对患有实体瘤的人类或动物受试者进行治疗,方法是向受试者施用治疗有效量的一氧化氮(NO)合酶抑制剂和化合物,该化合物是公式(A)的咪唑或1,2,4-三唑衍生物,其中X选自以下组:##STR2##其中R为氢或C.sub.1-C.sub.6烷基;R'.sub.1至R'.sub.5中的每一个独立地选自以下组:氢,C.sub.1-C.sub.6烷基,羟基(C.sub.1-C.sub.6烷基),苯基,(C.sub.1-C.sub.6烷基)苯基和苯基(C.sub.1-C.sub.6烷基);m为0或1;n为1或2;Z'代表具有通过分子内环化反应进行喷出的潜力的离去基团,且不带负电荷;或其生理上可接受的酸加成盐。